KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $8.3 million.

  • CRISPR Therapeutics AG's Gains from Investment Securities fell 4514.02% to $8.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.2 million, marking a year-over-year decrease of 6050.36%. This contributed to the annual value of $6.7 million for FY2025, which is 742.29% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Gains from Investment Securities stood at $8.3 million for Q4 2025, which was down 4514.02% from $6.7 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's Gains from Investment Securities' 5-year high stood at $128.9 million during Q4 2021, with a 5-year trough of $969000.0 in Q1 2023.
  • In the last 5 years, CRISPR Therapeutics AG's Gains from Investment Securities had a median value of $7.6 million in 2022 and averaged $15.9 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 9101.62% in 2023, then surged by 63935.49% in 2024.
  • CRISPR Therapeutics AG's Gains from Investment Securities (Quarter) stood at $128.9 million in 2021, then crashed by 58.85% to $53.1 million in 2022, then tumbled by 91.02% to $4.8 million in 2023, then surged by 217.98% to $15.2 million in 2024, then tumbled by 45.14% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q4 2025, $6.7 million for Q3 2025, and $7.4 million during Q2 2025.